Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly’s Lebrikizumab Atopic Dermatitis Monotherapy Trials
The Pharma Data
JUNE 7, 2022
. “We look forward to providing an important new medicine and helping patients find the relief they so desperately seek from the varied and debilitating symptoms of this disease, contingent upon FDA approval.” EASI=Eczema Area and Severity Index, EASI-75=75 percent reduction in EASI from baseline to Week 16.
Let's personalize your content